Skip to main content
. 2018 Jun 22;9(48):28903–28909. doi: 10.18632/oncotarget.25627

Table 2. Treatment response to combined immunotherapy with ipilimumab and pembrolizumab in cutaneous and uveal melanoma.

Best Response, N (%) Cutaneous Melanoma (N = 24) Uveal Melanoma (N = 9)
PD 8 (33) 4 (44)
SD 7 (29) 5 (56)
PR 7 (29) 0 (0)
CR 2 (8) 0 (0)

Abbreviations: PD = progressive disease, SD = stable disease, PR = partial response, CR = complete response.